Disease Landscape and Forecast Insights

The multiple sclerosis (MS) therapy market continues to evolve, with each new food and drug administration approved disease-modifying therapy (DMT) further expanding treatment choices. The newest…

Clarivate Epidemiology’s coverage of fragile X syndrome (FXS) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France…

Amyotrophic lateral sclerosis (ALS) is a disorder of the central nervous system characterized by motor neuron degeneration. ALS causes progressive weakness and atrophy of the muscles and loss of…

Clarivate Epidemiology’s coverage of cutaneous lupus erythematosus (CLE) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United…

Clarivate Epidemiology’s coverage of retinal vein occlusion (RVO) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of RVO for…

Clarivate Epidemiology’s coverage of retinal vein occlusion (RVO) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of RVO for…

Clarivate’s Epidemiology’s coverage of retinal vein occlusion comprises epidemiological estimates of key patient populations. We report the prevalence of retinal vein occlusion for each country…

Clarivate’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key retinal vein occlusion patient populations covering 171 countries…

Regional Forecast is an add on offering from Clarivate’s Company & Drugs (C&D) that renders extended coverage of existing C&D proprietary data. With increasing demand to analyze the data in much…

Venous thromboembolism (VTE) is the obstruction of a vein caused by a thrombus. It consists of deep vein thrombosis (DVT) and pulmonary embolism (PE), depending on the location of the obstruction…

Although chemotherapy has traditionally been the cornerstone of ovarian cancer treatment, angiogenesis and PARP inhibitors have revolutionized the treatment landscape, impacting prescribing…

Clarivate Epidemiology’s coverage of osteopenia (OPE) comprises epidemiological estimates of key patient populations in seven emerging pharmaceutical markets. We report the prevalence of OPE for…